AXPAXLI Demonstrates Unmatched Durability in Wet AMD Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy OCUL?
Source: Newsfilter
- Clinical Trial Results: In the SOL-1 Phase 3 trial, 74.1% of subjects maintained vision at Week 36 with AXPAXLI, a 17.5% improvement over the aflibercept group, highlighting its significant efficacy in wet AMD treatment.
- Disease Control Capability: The median time to achieve a ≥30 uM increase in Central Subfield Thickness (CSFT) from Week 8 to Week 52 was 39 weeks for the AXPAXLI group, compared to 16 weeks for the aflibercept group, indicating a 23-week advantage in disease control.
- Sustained Visual Outcomes: At Week 52, AXPAXLI subjects showed an average improvement of +11.8 ETDRS letters in visual acuity, significantly higher than the +8.5 letters in the aflibercept group, demonstrating consistent effectiveness across different baseline vision quartiles.
- Good Safety Profile: Among all AXPAXLI subjects with vitreous floaters, drug particles were no longer visible after an average of 20 weeks, indicating a favorable safety profile that does not impair vision, thereby enhancing confidence in clinical adoption.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCUL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCUL
Wall Street analysts forecast OCUL stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.760
Low
20.00
Averages
23.43
High
31.00
Current: 8.760
Low
20.00
Averages
23.43
High
31.00
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AXPAXLI Demonstrates Unmatched Durability in Wet AMD Treatment
- Clinical Trial Results: In the SOL-1 Phase 3 trial, 74.1% of subjects maintained vision at Week 36 with AXPAXLI, a 17.5% improvement over the aflibercept group, highlighting its significant efficacy in wet AMD treatment.
- Disease Control Capability: The median time to achieve a ≥30 uM increase in Central Subfield Thickness (CSFT) from Week 8 to Week 52 was 39 weeks for the AXPAXLI group, compared to 16 weeks for the aflibercept group, indicating a 23-week advantage in disease control.
- Sustained Visual Outcomes: At Week 52, AXPAXLI subjects showed an average improvement of +11.8 ETDRS letters in visual acuity, significantly higher than the +8.5 letters in the aflibercept group, demonstrating consistent effectiveness across different baseline vision quartiles.
- Good Safety Profile: Among all AXPAXLI subjects with vitreous floaters, drug particles were no longer visible after an average of 20 weeks, indicating a favorable safety profile that does not impair vision, thereby enhancing confidence in clinical adoption.
See More
Ocular Therapeutix Shares Surge 10.45% Ahead of Key Conferences
- Stock Surge: Ocular Therapeutix shares rose 10.45% on Thursday, closing at $9.30, reflecting strong investor anticipation for upcoming business updates, particularly from key presentations at several conferences.
- Key Conference Participation: Chief Scientific Officer Jeffrey Heier and Chief Development Officer Peter Kaiser are set to speak at the 14th Annual Vit-Buckle Society Meeting in Las Vegas on April 11, discussing management strategies for Neovascular AMD, which could influence the company's future treatment directions.
- CEO Presentation: Chairman and CEO Pravin Dugel will present at the Congreso Nacional de Oftalmologia in Buenos Aires on April 15, covering Tyrosine Kinase Inhibitors and the current state of treatments for diabetic retinal disease, likely drawing investor interest.
- Clinical Trial Progress: Investors are keenly awaiting updates on Ocular Therapeutix's investigational drug Axpaxli, currently in a phase 3 trial for wet AMD and non-proliferative diabetic retinopathy, with potential implications for stock price movement following the conferences.
See More
Ocular Therapeutix to Participate in Multiple Scientific Conferences
- Conference Participation: Ocular Therapeutix is set to participate in several scientific conferences in April 2026, showcasing its advancements in wet age-related macular degeneration (wet AMD), which is expected to enhance its influence in the ophthalmic biopharmaceutical sector.
- VBS Conference Presentation: At the 14th Annual Vit-Buckle Society Meeting from April 9-11, Ocular will present additional data from the SOL-1 Phase 3 clinical trial on April 11, further solidifying its leadership in managing neovascular AMD.
- CNO 2026 Engagement: Ocular will also deliver multiple presentations at the Congreso Nacional de Oftalmologia 2026 from April 15-17, covering the role of TKIs and the current state of diabetic retinal disease treatment, demonstrating its expertise in ocular therapies.
- Pipeline Updates: AXPAXLI™ (OTX-TKI) is currently in Phase 3 trials, and Ocular is evaluating next steps for other products like OTX-TIC, reflecting the company's ongoing commitment to innovation in ocular treatments.
See More
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
AXPAXLI Demonstrates Unmatched Durability in Wet AMD Treatment
- Clinical Trial Results: In the SOL-1 Phase 3 trial, 74.1% of subjects maintained vision at Week 36 with AXPAXLI, a 17.5% improvement over the aflibercept group, highlighting its significant efficacy in wet AMD treatment.
- Disease Control Capability: The median time to achieve a ≥30 uM increase in Central Subfield Thickness (CSFT) from Week 8 to Week 52 was 39 weeks for the AXPAXLI group, compared to 16 weeks for the aflibercept group, indicating a 23-week advantage in disease control.
- Sustained Visual Outcomes: At Week 52, AXPAXLI subjects showed an average improvement of +11.8 ETDRS letters in visual acuity, significantly higher than the +8.5 letters in the aflibercept group, demonstrating consistent effectiveness across different baseline vision quartiles.
- Good Safety Profile: Among all AXPAXLI subjects with vitreous floaters, drug particles were no longer visible after an average of 20 weeks, indicating a favorable safety profile that does not impair vision, thereby enhancing confidence in clinical adoption.
See More
Ocular Therapeutix Shares Surge 10.45% Ahead of Key Conferences
- Stock Surge: Ocular Therapeutix shares rose 10.45% on Thursday, closing at $9.30, reflecting strong investor anticipation for upcoming business updates, particularly from key presentations at several conferences.
- Key Conference Participation: Chief Scientific Officer Jeffrey Heier and Chief Development Officer Peter Kaiser are set to speak at the 14th Annual Vit-Buckle Society Meeting in Las Vegas on April 11, discussing management strategies for Neovascular AMD, which could influence the company's future treatment directions.
- CEO Presentation: Chairman and CEO Pravin Dugel will present at the Congreso Nacional de Oftalmologia in Buenos Aires on April 15, covering Tyrosine Kinase Inhibitors and the current state of treatments for diabetic retinal disease, likely drawing investor interest.
- Clinical Trial Progress: Investors are keenly awaiting updates on Ocular Therapeutix's investigational drug Axpaxli, currently in a phase 3 trial for wet AMD and non-proliferative diabetic retinopathy, with potential implications for stock price movement following the conferences.
See More
Ocular Therapeutix to Participate in Multiple Scientific Conferences
- Conference Participation: Ocular Therapeutix is set to participate in several scientific conferences in April 2026, showcasing its advancements in wet age-related macular degeneration (wet AMD), which is expected to enhance its influence in the ophthalmic biopharmaceutical sector.
- VBS Conference Presentation: At the 14th Annual Vit-Buckle Society Meeting from April 9-11, Ocular will present additional data from the SOL-1 Phase 3 clinical trial on April 11, further solidifying its leadership in managing neovascular AMD.
- CNO 2026 Engagement: Ocular will also deliver multiple presentations at the Congreso Nacional de Oftalmologia 2026 from April 15-17, covering the role of TKIs and the current state of diabetic retinal disease treatment, demonstrating its expertise in ocular therapies.
- Pipeline Updates: AXPAXLI™ (OTX-TKI) is currently in Phase 3 trials, and Ocular is evaluating next steps for other products like OTX-TIC, reflecting the company's ongoing commitment to innovation in ocular treatments.
See More
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
